New Investigators. We are requesting $150,000 per year to support 2-3 new investigators for one to three years for start-up of their research. The recruitments occur in partnership with Departments, and can be initiated by either partner. The funds are intended to guarantee technical support and supplies for junior-level investigators. However, it is possible that these funds could be combined into a larger package for a more senior individual. The University of Virginia will pay for the salary and most of the equipment costs of these recruits, and in addition the Cancer Center has available $500,000 per year from the School of Medicine to aid in recruitment. Further matching almost invariably is obtained from the Department that we partner with in these recruitments. Thus, funds from the CCSG permit the Cancer Center to leverage a relatively modest investment into a considerable influence on the future of the University of Virginia Health Sciences Center. As described in Section 6.3, our focus for recruitments during the next funding period will be to bolster clinical investigations, strengthen cancer-focused basic and translational research, and strengthen Cancer Control. Clinical investigators will be chosen who will work well within our collaborative environment, and who have an interest and expertise in molecularly targeted therapies, biomarkers, and imaging, especially in the major solid tumors. Translational investigators will be recruited to help development of translational working groups, especially in the areas of immunotherapy, women's oncology, prostate cancer, and aerodigestive cancers. In addition, we will look for opportunities to partner with basic science departments, to recruit outstanding cancer-focused basic scientists, with the Departments of Biomedical Engineering and Radiology to bolster our capability in cancer imaging, and with the Department of Public Health Sciences, to strengthen the foundation for movement toward Comprehensive status.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-20
Application #
8104138
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-02-01
Budget End
2011-01-31
Support Year
20
Fiscal Year
2010
Total Cost
$100,815
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications